Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

HSCT: Donor selection for patients with ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 294

Prof Sebastian Giebel - The Maria Skłodowska-Curie Institute of Oncology, Gliwice, Poland

Prof Sebastian Giebel speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about the importance of donor selection in haematopoietic stem cell transplantation (HSCT).

He describes the selection process, where matched siblings are usually the first choice for donation and that the availability of donors is no longer a limiting factor.

Prof Giebel also states that haploidentical transplants are equivalent to unrelated donor transplants - which can be offered to most patients.

He describes that large registries and retrospective data is used to conduct comparisons between the two donor types and discusses the future use of HSCT.


Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation